{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:52:05Z","timestamp":1788209525805,"version":"build-2803163510"},"reference-count":79,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":225,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The therapeutic landscape of Graves\u2019 hyperthyroidism has been rapidly evolving in the past few years. There has been a shift worldwide toward antithyroid drugs as the preferred first-line therapy with significant interest in thyroid function preservation, even if it requires more than 2 years of antithyroid drug treatment. This approach, long term antithyroid drug therapy, has gained traction as a therapeutic option after it has been shown to be safe and associated with significantly higher rates of remission than the traditional 18-month course of medical treatment. In parallel, we see, after 80 years of antithyroid drugs as the only medical therapy available for Graves\u2019 disease, a strong interest in new drug development that follows more closely the pathophysiology of the disease. These approaches span the spectrum of targeting antigen presentation, B cell activation, TSHR antibody cycle and TSHR signaling. Separately, advances in wearable devices and artificial intelligence models present new opportunities for more timely diagnosis, monitoring, and treatment of patients with Graves\u2019 disease. Finally, new therapies will pose novel challenges in the management of patients that will necessitate adjustments to our clinical practices and development of guidelines suited for these new therapeutic options.<\/jats:p>","DOI":"10.1530\/etj-25-0078","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T09:30:15Z","timestamp":1751880615000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":9,"title":["The evolving therapeutic landscape of Graves\u2019 disease in adults: present and future"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-8125","authenticated-orcid":true,"given":"Marius N","family":"Stan","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Nutrition and Metabolism, Mayo Clinic 1 , , ,","place":["Rochester, Minnesota, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Dosiou","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Stanford University School of Medicine 2 , , ,","place":["Stanford, California, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"2026070713003012900_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-199401000-00001","article-title":"Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases","volume":"73","author":"Fatourechi","year":"1994","journal-title":"Medicine"},{"key":"2026070713003012900_bib3","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1210\/jc.2002-020746","article-title":"Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period","volume":"87","author":"Fatourechi","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"2026070713003012900_bib5","first-page":"474","article-title":"Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in Graves' disease","volume":"54","author":"Hertz","year":"1946","journal-title":"West J Surg Obstet Gynecol"},{"key":"2026070713003012900_bib6","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1984.03340370075036","article-title":"Landmark article May 8, 1943: Treatment of hyperthyroidism with thiourea and thiouracil. By E.B. Astwood","volume":"251","author":"Astwood","year":"1984","journal-title":"JAMA"},{"key":"2026070713003012900_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/cen.12688","article-title":"A 2013 European survey of clinical practice patterns in the management of Graves' disease","volume":"84","author":"Bartalena","year":"2016","journal-title":"Clin Endocrinol"},{"key":"2026070713003012900_bib8","doi-asserted-by":"crossref","first-page":"132041","DOI":"10.1186\/1687-9856-2009-132041","article-title":"Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use","volume":"2009","author":"Rivkees","year":"2009","journal-title":"Int J Pediatr Endocrinol"},{"key":"2026070713003012900_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the management of Graves' hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"2026070713003012900_bib10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1507\/endocrj.EJ16-0336","article-title":"2016 Guidelines for the management of thyroid storm from the Japan Thyroid Association and Japan Endocrine Society (First edition)","volume":"63","author":"Satoh","year":"2016","journal-title":"Endocr J"},{"key":"2026070713003012900_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-98-1-26","article-title":"Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose","volume":"98","author":"Cooper","year":"1983","journal-title":"Ann Intern Med"},{"key":"2026070713003012900_bib12","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1210\/jc.2011-2221","article-title":"Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease","volume":"97","author":"Watanabe","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib13","first-page":"CD003420","article-title":"Antithyroid drug regimen for treating Graves' hyperthyroidism","volume":"2010","author":"Abraham","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026070713003012900_bib14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJM198008073030603","article-title":"Carbimazole and the autoimmune response in Graves' disease","volume":"303","author":"McGregor","year":"1980","journal-title":"N Engl J Med"},{"key":"2026070713003012900_bib15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(77)92719-2","article-title":"Value of thyroid-stimulating-antibody determinations in predicting short-term thyrotoxic relapse in Graves' disease","volume":"1","author":"Davies","year":"1977","journal-title":"Lancet"},{"key":"2026070713003012900_bib16","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/jcem-67-4-656","article-title":"Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease","volume":"67","author":"Codaccioni","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/thy.1991.1.293","article-title":"Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease","volume":"1","author":"Werner","year":"1991","journal-title":"Thyroid"},{"key":"2026070713003012900_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2796.1995.tb00914.x","article-title":"Short-term treatment of Graves' disease with methimazole in high versus low doses","volume":"238","author":"Jorde","year":"1995","journal-title":"J Intern Med"},{"key":"2026070713003012900_bib19","first-page":"2470","article-title":"Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease","volume":"80","author":"Paschke","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","article-title":"Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs","volume":"49","author":"Benker","year":"1998","journal-title":"Clin Endocrinol"},{"key":"2026070713003012900_bib21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1046\/j.1365-2265.1998.00446.x","article-title":"A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole","volume":"48","author":"Grebe","year":"1998","journal-title":"Clin Endocrinol"},{"key":"2026070713003012900_bib22","author":"National Guideline Centre (UK)"},{"key":"2026070713003012900_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.1991.1.129","article-title":"Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States","volume":"1","author":"Wartofsky","year":"1991","journal-title":"Thyroid"},{"key":"2026070713003012900_bib24","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/thy.2016.0222","article-title":"Antithyroid drugs-the most common treatment for Graves' disease in the United States: a nationwide population-based study","volume":"26","author":"Brito","year":"2016","journal-title":"Thyroid"},{"key":"2026070713003012900_bib25","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1210\/clinem\/dgae222","article-title":"A 2023 International Survey of clinical practice patterns in the management of graves disease: a decade of change","volume":"109","author":"Villagelin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2019.0132","article-title":"Patterns of use, efficacy, and safety of treatment options for patients with Graves' disease: a nationwide population-based study","volume":"30","author":"Brito","year":"2020","journal-title":"Thyroid"},{"key":"2026070713003012900_bib27","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1089\/thy.2019.0085","article-title":"The long-term outcome of treatment for Graves' hyperthyroidism","volume":"29","author":"Sjolin","year":"2019","journal-title":"Thyroid"},{"key":"2026070713003012900_bib28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1530\/EJE-20-1490","article-title":"Preferences of patients and clinicians for treatment of Graves' disease: a discrete choice experiment","volume":"184","author":"van Kinschot","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2026070713003012900_bib29","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with Graves' disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"key":"2026070713003012900_bib30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40618-019-01054-1","article-title":"Safety of long-term antithyroid drug treatment? A systematic review","volume":"42","author":"Azizi","year":"2019","journal-title":"J Endocrinol Investig"},{"key":"2026070713003012900_bib31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1089\/thy.2017.0681","article-title":"An online survey of hypothyroid patients demonstrates prominent dissatisfaction","volume":"28","author":"Peterson","year":"2018","journal-title":"Thyroid"},{"key":"2026070713003012900_bib32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/cen.14340","article-title":"Patient satisfaction and quality of life in hypothyroidism: an online survey by the British thyroid foundation","volume":"94","author":"Mitchell","year":"2021","journal-title":"Clin Endocrinol"},{"key":"2026070713003012900_bib33","first-page":"1158","article-title":"The impact of hypothyroidism on satisfaction with care and treatment and everyday living: results from E-Mode patient self-assessment of thyroid therapy, a cross-sectional, International Online Patient Survey","volume":"32","author":"Perros","year":"2022","journal-title":"Thyroid"},{"key":"2026070713003012900_bib34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/thy.2018.0165","article-title":"Incidence of neonatal hyperthyroidism among newborns of graves' disease patients treated with radioiodine therapy","volume":"29","author":"Yoshihara","year":"2019","journal-title":"Thyroid"},{"key":"2026070713003012900_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.25072","article-title":"Cancer risk after radioactive iodine treatment for hyperthyroidism: a systematic review and meta-analysis","volume":"4","author":"Shim","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026070713003012900_bib36","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1530\/EJE-18-0678","article-title":"ANNIVERSARY REVIEW: antithyroid drug therapy: 70 years later","volume":"179","author":"Burch","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026070713003012900_bib37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/clinem\/dgad538","article-title":"Outcomes of patients with Graves disease 25 years after initiating antithyroid drug therapy","volume":"109","author":"Meling Stokland","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib38","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF03346433","article-title":"Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study","volume":"31","author":"Mazza","year":"2008","journal-title":"J Endocrinol Investig"},{"key":"2026070713003012900_bib39","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/thy.2011.0039","article-title":"Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy","volume":"21","author":"Laurberg","year":"2011","journal-title":"Thyroid"},{"key":"2026070713003012900_bib40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-013-9895-0","article-title":"Predictors of long-term remission in patients with Graves' disease: a single center experience","volume":"44","author":"Anagnostis","year":"2013","journal-title":"Endocrine"},{"key":"2026070713003012900_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/EJE-14-0704","article-title":"A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice","volume":"172","author":"Liu","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2026070713003012900_bib42","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2016.0652","article-title":"Long-term antithyroid drug treatment: a systematic review and meta-analysis","volume":"27","author":"Azizi","year":"2017","journal-title":"Thyroid"},{"key":"2026070713003012900_bib43","doi-asserted-by":"crossref","first-page":"e1881","DOI":"10.1210\/clinem\/dgae456","article-title":"Approach to the patient considering long-term antithyroid drug therapy for Graves' disease","volume":"109","author":"Azizi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib44","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0031","article-title":"Long-term methimazole therapy in Graves' hyperthyroidism and adverse reactions: a Danish multicenter study","volume":"11","author":"Karmisholt","year":"2022","journal-title":"Eur Thyroid J"},{"key":"2026070713003012900_bib45","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/MED.0000000000000656","article-title":"Long-term antithyroid drug therapy","volume":"28","author":"Cooper","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026070713003012900_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1507\/endocrj.EJ18-0418","article-title":"The long-term follow-up of patients with thionamide-treated Graves' hyperthyroidism","volume":"66","author":"Bandai","year":"2019","journal-title":"Endocr J"},{"key":"2026070713003012900_bib47","article-title":"Long-term antithyroid drug treatment: trends in serum TSH and TSH receptor antibody changes in patients with Graves' disease","volume":"18","author":"Okamura","year":"2020","journal-title":"Int J Endocrinol Met"},{"key":"2026070713003012900_bib48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/EJE-16-0986","article-title":"External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients","volume":"176","author":"Struja","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2026070713003012900_bib49","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","article-title":"Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management","volume":"41","author":"Masiello","year":"2018","journal-title":"J Endocrinol Investig"},{"key":"2026070713003012900_bib50","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1055\/a-0974-3991","article-title":"External validation of the GREAT score in Turkish patients with Graves' hyperthyroidism treated with the titration regimen method of antithyroid drugs: a multicenter study","volume":"51","author":"Zuhur","year":"2019","journal-title":"Horm Metab Res"},{"key":"2026070713003012900_bib51","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eprac.2024.12.011","article-title":"A predictive model for Graves' disease recurrence after antithyroid drug therapy: a retrospective multicenter cohort study","volume":"31","author":"El Kawkgi","year":"2024","journal-title":"Endocr Pract"},{"key":"2026070713003012900_bib53","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2265.2010.03831.x","article-title":"ORIGINAL ARTICLE: monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample","volume":"73","author":"Evans","year":"2010","journal-title":"Clin Endocrinol"},{"key":"2026070713003012900_bib54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13317-011-0025-9","article-title":"In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70)","volume":"3","author":"Furmaniak","year":"2012","journal-title":"Auto Immun Highlights"},{"key":"2026070713003012900_bib55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13317-019-0121-9","article-title":"Preclinical studies on the toxicology, pharmacokinetics and safety of K1-70(TM) a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity","volume":"10","author":"Furmaniak","year":"2019","journal-title":"Auto Immun Highlights"},{"key":"2026070713003012900_bib56","first-page":"1597","article-title":"Blocking the thyrotropin receptor with K1-70 in a patient with follicular thyroid cancer, Graves' disease, and Graves' ophthalmopathy","volume":"31","author":"Ryder","year":"2021","journal-title":"Thyroid"},{"key":"2026070713003012900_bib57","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70(TM) targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-results from a phase I clinical trial","volume":"96","author":"Furmaniak","year":"2022","journal-title":"Clin Endocrinol"},{"key":"2026070713003012900_bib58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/thy.2018.0349","article-title":"A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves' orbitopathy","volume":"29","author":"Marcinkowski","year":"2019","journal-title":"Thyroid"},{"key":"2026070713003012900_bib59","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1210\/en.2013-1835","article-title":"A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice","volume":"155","author":"Neumann","year":"2014","journal-title":"Endocrinology"},{"key":"2026070713003012900_bib60","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fendo.2016.00130","article-title":"TSH receptor signaling abrogation by a novel small molecule","volume":"7","author":"Latif","year":"2016","journal-title":"Front Endocrinol"},{"key":"2026070713003012900_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117258","article-title":"Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist","volume":"84","author":"Karstens","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"2026070713003012900_bib62","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, Batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib63","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/clinem\/dgz013","article-title":"A novel Anti-CD40 monoclonal antibody, iscalimab, for control of Graves hyperthyroidism-a proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.691781","article-title":"Precision medicine in Graves' disease: CD40 gene variants predict clinical response to an Anti-CD40 monoclonal antibody","volume":"12","author":"Faustino","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026070713003012900_bib65","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid"},{"key":"2026070713003012900_bib66","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fendo.2020.00367","article-title":"Corticosteroid pulse therapy for Graves' ophthalmopathy reduces the relapse rate of Graves' hyperthyroidism","volume":"11","author":"Le Moli","year":"2020","journal-title":"Front Endocrinol"},{"key":"2026070713003012900_bib67","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/clinem\/dgae472","article-title":"Effects of low-dose methotrexate with methimazole in patients with graves' disease: results of a randomized clinical trial","volume":"110","author":"Xie","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1168936","article-title":"Azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial","volume":"14","author":"Allam","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026070713003012900_bib69","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1210\/clinem\/dgab763","article-title":"Adjuvant rituximab-exploratory trial in young people with Graves disease","volume":"107","author":"Cheetham","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib70","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib71","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41574-024-01003-w","article-title":"The relationship between the gut microbiota and thyroid disorders","volume":"20","author":"Ludgate","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026070713003012900_bib72","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1210\/clinem\/dgad030","article-title":"Gut microbiome associated with Graves disease and graves orbitopathy: the INDIGO multicenter European study","volume":"108","author":"Biscarini","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713003012900_bib73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40168-020-00952-4","article-title":"Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease","volume":"9","author":"Moshkelgosha","year":"2021","journal-title":"Microbiome"},{"key":"2026070713003012900_bib74","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1007\/s00330-019-06303-8","article-title":"Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves' disease","volume":"29","author":"Lang","year":"2019","journal-title":"Eur Radiol"},{"key":"2026070713003012900_bib75","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1089\/thy.2024.0177","article-title":"The two-year results of using radiofrequency ablation as a novel treatment for persistent or relapsed Graves' disease: a prospective study","volume":"34","author":"Fung","year":"2024","journal-title":"Thyroid"},{"key":"2026070713003012900_bib76","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jss.2017.06.091","article-title":"The long-term outcomes of thyroid function after subtotal thyroidectomy for Graves' hyperthyroidism","volume":"220","author":"Lin","year":"2017","journal-title":"J Surg Res"},{"key":"2026070713003012900_bib77","article-title":"Hyperthyroidism due to Graves disease after radiofrequency ablation","volume":"1","author":"McAninch","year":"2023","journal-title":"JCEM Case Rep"},{"key":"2026070713003012900_bib78","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jadohealth.2022.03.021","article-title":"Wearable technology leads to initial workup of Graves' disease in an adolescent female","volume":"71","author":"Shanefield","year":"2022","journal-title":"J Adolesc Health"},{"key":"2026070713003012900_bib79","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.8119","article-title":"Clinical feasibility of continuously monitored data for heart rate, physical activity, and sleeping by wearable activity trackers in patients with thyrotoxicosis: protocol for a prospective longitudinal observational study","volume":"7","author":"Lee","year":"2018","journal-title":"JMIR Res Protoc"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/4\/ETJ-25-0078.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/4\/ETJ-25-0078.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0078\/34870\/etj-25-0078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0078\/34870\/etj-25-0078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:30:21Z","timestamp":1783445421000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/4\/e250078\/4726\/The-evolving-therapeutic-landscape-of-Graves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0078","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"article-number":"e250078"}}